{"name":"Xiangbei Welman Pharmaceutical Co., Ltd","slug":"xiangbei-welman-pharmaceutical-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"xin te mie","genericName":"xin te mie","slug":"xin-te-mie","indication":"Type 2 diabetes","status":"marketed"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Piperacillin Sodium and Sulbactam Sodium","genericName":"Piperacillin Sodium and Sulbactam Sodium","slug":"piperacillin-sodium-and-sulbactam-sodium","indication":"Bacterial infections caused by susceptible organisms including intra-abdominal infections, gynecological infections, skin and soft tissue infections, and respiratory tract infections","status":"marketed"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"xinzhijun","genericName":"xinzhijun","slug":"xinzhijun","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"xin te mie","genericName":"xin te mie","slug":"xin-te-mie","phase":"marketed","mechanism":"Xin te mie is a small molecule that acts as a selective inhibitor of the sodium-glucose cotransporter 2 (SGLT2).","indications":["Type 2 diabetes","Hypertension"],"catalyst":""},{"name":"Piperacillin Sodium and Sulbactam Sodium","genericName":"Piperacillin Sodium and Sulbactam Sodium","slug":"piperacillin-sodium-and-sulbactam-sodium","phase":"marketed","mechanism":"Piperacillin inhibits bacterial cell wall synthesis by binding penicillin-binding proteins, while sulbactam inhibits bacterial β-lactamases to prevent antibiotic degradation.","indications":["Bacterial infections caused by susceptible organisms including intra-abdominal infections, gynecological infections, skin and soft tissue infections, and respiratory tract infections","Polymicrobial infections including those with β-lactamase-producing organisms"],"catalyst":""},{"name":"xinzhijun","genericName":"xinzhijun","slug":"xinzhijun","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":3,"phaseCounts":{"marketed":2,"phase_2":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}